Tumor angiogenesis and anti-angiogenic therapies

Human Antibodies

Volumn 22, Issue 1-2, 2013, Pages 15-19

  Shahneh, Fatemeh Zare ^a   Baradaran, Behzad ^a   Zamani, Fatemeh ^a   Aghebati Maleki, Leili ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Anti angiogenic therapy; Tumor angiogenesis; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR; LAPATINIB; PACLITAXEL; PAZOPANIB; PEGAPTANIB; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PLACENTA PROTEIN; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; BREAST CANCER; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG POTENTIATION; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RECURRENT CANCER; RETINA MACULA AGE RELATED DEGENERATION; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; THROMBOSIS; TUMOR GROWTH; VASCULAR ENDOTHELIUM; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; PYRROLES; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84889809011     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-130267     Document Type: Article

References (60)

1. A. Armulik, G. Genov and C. Betsholtz, Pericytes: Developmental physiological and pathological perspectives problems and promises, Dev Cell 21 (2011), 193-215.
2. A.C. Taylor, L.M. Seltz, P.A. Yates and S.M. Peirce, Chronic Whole-Body Hypoxia Induces Intussusceptive Angiogenesis and Microvascular Remodeling in the Mouse Retina, Microvasc Res 79 (2010), 93-101.
3. A.E. Koch, Review: Angiogenesis: Implications for Rheumatoid Arthritis, Arthritis Rheum 41 (1998), 951-962.
4. A.N. Makanya, R. Hlushchuk and V.G. Djonov, Intussusceptive Angiogenesis and Its Role in Vascular Morphogenesis Patterning and Remodeling, Angiogenesis 12 (2009), 113- 123.
5. C. Fischer, B. Jonckx and M. Mazzone, Anti-PLGF inhibits growth of VEGF(R)- inhibitor-resistant tumors without affecting healthy vessels, Cell 131 (2007), 463-475.
6. C. Fischer, M. Mazzone, B Jonckx and P. Carmeliet, Flt1 and its ligands VEGFb and PLGF: drug targets for anti-angiogenic therapy, Nat Rev Cancer 8 (2008), 942-956.
7. D. Hanahan, Signaling vascular morphogenesis and maintenance, Science 277 (1997), 48-50.
8. D. Miles, N. Harbeck, B. Escudier, H. Hurwitz, B. Mueller and F. Sirzén, Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials, J Clin Oncol 29 (2010), 83-88.
9. D. Ribatti, Judah Folkman: A pioneer in the study of angiogenesis, Angiogenesis 11 (2008), 3-10.
10. D.A. Hanahan, Flanking attack on cancer, Nat Med 4 (1998), 13-14.
11. D.J. Hicklin and L.M. Ellis, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J Clin Oncol 23 (2005), 1011-1027.
12. F. Blasi and P. Carmeliet, Upar: A versatile signalling orchestrator, Nat Rev Mol Cell Biol 3 (2002), 932-943.
13. G. Bergers and D. Hanahan, Modes of resistance to antiangiogenic therapy, Nat Rev Cancer 8 (2008), 592-603.
14. H. Gerhardt and H. Semb, Pericytes: Gatekeepers in tumour cell metastasis?, J MolMed 11 (2008), 135-144.
15. H. Izzedine, S. Ederhy, F. Goldwasser, J.C. Soria, G. Milano, A. Cohen, D. Khayat and J.P. Spano, Management of hypertension in angiogenesis inhibitor-treated patients, Ann Oncol 20 (2009), 807-815.
16. H.J. Burstein, A.D. Elias, H. Rugo, M.A. Cobleigh, A.C. Wolff and K.D. Miller, Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor in patients with metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol 26 (2008), 810-816.
17. H.G. Augustin, G.Y. Koh, G. Thurston and K. Alitalo, Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system, Nat Rev Mol Cell Biol 10 (2009), 165-177.
18. H.M. Eilken and R.H. Adams, Dynamics of endothelial cell behavior in sprouting angiogenesis, Curr Opin Cell Biol 22 (2010), 617-625.
19. H.M. Verheul and H.M. Pinedo, possible molecular mechanisms involved in the toxicity of angiogenesis inhibition, Nat Rev Cancer 7 (2007), 475-485.
20. J. Folkman, Angiogenesis in cancer vascular rheumatoid and other disease, Nat Med 1 (1995), 27-31.
21. J. Folkman, Tumor Angiogenesis: Therapeutic Implications, N Engl J Med 285 (1971), 1182-1186.
22. J. Holash, S.J. Wiegand and G.D. Yancopoulos, New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF, Oncogene 18 (1999), 5356-5362.
23. J. Oliner, H. Min and J. Leal, Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2, Cancer Cell 6 (2004), 507-516.
24. J. Paulsson, T. Sjoblom, P. Micke, F. Ponten, G. Landberg and A. Ostman, Prognostic significance of stromal plateletderived growth factor beta-receptor expression in human breast cancer, Am J Pathol 175 (2009), 334-341.
25. J. Powell, Update on hemangiomas and vascular malformations, Curr Opin Pediatr 11 (1999), 457-463.
26. J.A. Eble and S. Niland, The extracellular matrix of blood vessels, Curr Pharm Des 15 (2009), 1385-1400.
27. J.D. Hood, M. Bednarski, R. Frausto, S. Guccione, R.A. Reisfeld, R. Xiang and D.A. Cheresh, Tumor regression by targeted gene delivery to the neovasculature, Science 296 (2002), 2404-2407.
28. J.M. Ebos and R.S. Kerbel, Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis, Nat Rev Clin Oncol 8 (2011), 210-221.
29. K. Gaengel, G. Genove, A. Armulik and C. Betsholtz, Endothelialmural cell signaling in vascular development and angiogenesis arterioscler, Thromb Vasc Biol 29 (2009), 630- 638.
30. L. Seymour, D. Dajee and W.R. Bezwoda, Tissue Platelet Derived-Growth Factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer, Breast Cancer Res Treat 26 (1993), 247-252.
31. L.A. Dyer and C. Patterson, Development of the endothelium: An emphasis on heterogeneity, Semin Thromb Hemost 36 (2010), 227-235.
32. M. Paez-Ribes, E. Allen, J. Hudock, G. Bergers, D. Hanahan and O. Casanovas, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, Cancer Cell 15 (2009), 220-231.
33. M. Potente, H. Gerhardt and P. Carmeliet, Basic and therapeutic aspects of angiogenesis, Cell 146 (2011), 873-887.
34. M. Ratner, Genentech discloses safety concerns over avastin, Nat Biotechnol 22 (2004), 1004-1198.
35. M. Shibuya and L. Claesson-Welsh, Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis, Exp Cell Res 312 (2006), 549-560.
36. M.S. Gordon, D. Mendelson and G. Kato, Tumor angiogenesis and novel antiangiogenic strategies, Int J Cancer 126 (2010), 1777-1787.
37. N. Ferrara, VEGF-A: A critical regulator of blood vessel growth, Eur Cytokine Netw 20 (2009), 158-163.
38. N. Ferrara, VEGF and the quest for tumour angiogenesis factors, Nat Rev Cancer 2 (2002), 795-803.
39. N. Ferrara, K.J. Hillan, H.P. Gerber and W. Novotny, Discovery and development of bevacizumab, an anti-vegf antibody for treating cancer, Nat Rev Drug Discov 3 (2004), 391-400.
40. N. Ferrara and R.S. Kerbel, Angiogenesis as a therapeutic target, Nature 438 (2005), 967-974.
41. P. Carmeliet, Angiogenesis in life, disease and medicine, Nature 438 (2005), 932-936.
42. P. Carmeliet, Mechanisms of angiogenesis and arteriogenesis, Nat Med 6 (2000), 389-395.
43. P. Carmeliet and R.K. Jain, Molecular mechanisms and clinical applications of angiogenesis, Nature 473 (2011), 298-307.
44. P. Carmeliet, Y. Dor, JM. Herbert, D. Fukumura, M. Dewerchin, and E. Keshert, Role of HIF-1 alpha in hypoxiamediated apoptosis cell proliferation and tumour angiogenesis, Nature 394 (1998), 485-490.
45. P. Fraisl, M. Mazzone, T. Schmidt and P. Carmeliet, Regulation of angiogenesis by oxygen and metabolism, Dev Cell 16 (2009), 167-179.
46. P. Salven, A. Lymboussaki and P. Heikkila, vascular endothelial growth factors VEGF-b and VEGF-c are expressed in human tumors, Am J Pathol 153 (1998), 103-108.
47. R. Hlushchuk, A. Makanya and V. Djonov, Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again? Int J Dev Biol 55 (2011), 563-567.
48. R.H. Adams and K. Alitalo, Molecular regulation of angiogenesis and lymphangiogenesis, Nat Rev Mol Cell Biol 8 (2007), 464-478.
49. S. Goel, D. Duda, L. Xu, L. Munn, Y. Boucher, D. Fukumura and R.K. Jain, Normalization of the vasculature for treatment of cancer and other diseases, Physiol Rev 91 (2011), 1071- 1121.
50. S. Kässmeyer, J. Plendl, P. Custodis and M. Bahramsoltani, New insights in vascular development: vasculogenesis and endothelial progenitor cells, Anat Histol Embryol 38 (2009), 1- 11.
51. S.Weis and D. Cheresh, Tumor angiogenesis: molecular pathways and therapeutic targets, Nature Medicine 17 (2011), 1359-1370.
52. S.M. Hyder and G.M. Stancel, Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins, Mol Endocrinol 13 (1999), 806-811.
53. T. Kamba and D.M. McDonald, Mechanisms of adverse effects of anti-VEGF therapy for cancer, Br J Cancer 96 (2007), 1788-1795.
54. W.W. Li,M. Hutnik and G. Gehr, Antiangiogenesis in haematological malignancies, Br J Haematol 143 (2008), 622-631.
55. T. Schmidt and P. Carmeliet, Blood-vessel formation: Bridges that guide and unite, Nature 465 (2010), 697-699.
56. T.P. Padera, A.H. Kuo, T. Hoshida, S. Liao, D. Fukumura and R.K. Jain, Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib, Mol Cancer Ther 7 (2008), 2272-2279.
57. W. De Spiegelaere, C. Casteleyn, J. Plendl, M. Bahramsoltani, P. Simoens, V. Djonov and P. Cornillie, Intussusceptive angiogenesis: A biologically relevant form of angiogenesis, J Vasc Res 49 (2012), 390-404.
58. W. De Spiegelaere, P. Cornillie, C. Casteleyn, C. Burvenich and W. Van den Broeck, Detection of hypoxia inducible factors and angiogenic growth factors during foetal endochondral and intramembranous ossification, Anat Histol Embryol 39 (2010), 376-384.
59. W. Risau, Mechanisms of angiogenesis, Nature 386 (1997), 671-674.
60. Y. Cao, Direct role of pdgf-bb in lymphangiogenesis and lymphatic metastasis, Cell Cycle 4 (2005), 228-230.